Sanofi, GSK variant-specific Covid-19 shot found effective against Omicron

"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. Sanofi's Paris-listed shares and GSK's London-listed shares were both up more than 1% in morning trading.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u1GSzUg
via IFTTT